key: cord-0736137-hhei1q9e
authors: Castiglione, Filippo; Deb, Debashrito; Srivastava, Anurag P.; Liò, Pietro; Liso, Arcangelo
title: From infection to immunity: understanding the response to SARS-CoV2 through in-silico modeling
date: 2021-01-11
journal: bioRxiv
DOI: 10.1101/2020.12.20.423670
sha: a8ab17d66b1c612a21c8fe4cbeb7b8ad5144f925
doc_id: 736137
cord_uid: hhei1q9e

Background Immune system conditions of the patient is a key factor in COVID-19 infection survival. A growing number of studies have focused on immunological determinants to develop better biomarkers for therapies. Aim The dynamics of the insurgence of immunity is at the core of the both SARS-CoV-2 vaccine development and therapies. This paper addresses a fundamental question in the management of the infection: can we describe the insurgence (and the span) of immunity in COVID-19? The in-silico model developed here answers this question at individual (personalized) and population levels. We simulate the immune response to SARS-CoV-2 and analyze the impact of infecting viral load, affinity to the ACE2 receptor and age in the artificially infected population on the course of the disease. Methods We use a stochastic agent-based immune simulation platform to construct a virtual cohort of infected individuals with age-dependent varying degree of immune competence. We use a parameter setting to reproduce known inter-patient variability and general epidemiological statistics. Results We reproduce in-silico a number of clinical observations and we identify critical factors in the statistical evolution of the infection. In particular we evidence the importance of the humoral response over the cytotoxic response and find that the antibody titers measured after day 25 from the infection is a prognostic factor for determining the clinical outcome of the infection. Our modeling framework uses COVID-19 infection to demonstrate the actionable effectiveness of simulating the immune response at individual and population levels. The model developed is able to explain and interpret observed patterns of infection and makes verifiable temporal predictions. Within the limitations imposed by the simulated environment, this work proposes in a quantitative way that the great variability observed in the patient outcomes in real life can be the mere result of subtle variability in the infecting viral load and immune competence in the population. In this work we i) show the power of model predictions, ii) identify the clinical end points that could be more suitable for computational modeling of COVID-19 immune response, iii) define the resolution and amount of data required to empower this class of models for translational medicine purposes and, iv) we exemplify how computational modeling of immune response provides an important view to discuss hypothesis and design new experiments, in particular paving the way to further investigations about the duration of vaccine-elicited immunity especially in the view of the blundering effect of immunesenescence.

It represents a portion of, i) primary lymphatic organs where lymphocytes are formed and mature (i.e., mainly the red bone marrow and the thymus gland), ii) secondary lymphoid organs (e.g., a lymph node), which filters lymph, and where naïve B and T-cells are presented to antigens, and, iii) peripheral tissue which is dependent on the pathogen considered (in this case the lung).

While primary organs are just the source of lymphocytes equipped with a randomly generated receptor (actually only its complementarity-determining region, CDR), the secondary organs and the tissue are mapped onto a three-dimensional Cartesian lattice. The thymus is implicitly represented by the positive and negative selection of immature thymocytes [2] before they enter the lymphatic system [3] , while the bone marrow generates already immunocompetent B lymphocytes.

C-IMMSIM incorporates several working assumptions or immunological theories, most of which are regarded as established mechanisms, including the clonal selection theory of Burnet [4], [5] , the clonal deletion theory (e.g., thymus education of T lymphocytes) [2] , [6] , the hypermutation of antibodies [7]- [9] , the replicative senescence of T-cells, or the Hayflick limit (i.e., a limit in the number of cell divisions) [10] , [11] ,

T-cell anergy [12] , [13] and Ag-dose induced tolerance in B-cells [14] , [15] , the danger theory [ In C-IMMSIM each simulated time step corresponds to eight hours of real life. Cells diffuse randomly in the represented volume and interact among them. Upon specific recognition through receptor bindings, they perform actions which determine their functional behaviour. These actions are coded as probabilistic rules and define the transition of the interacting cell entities from one "condition" to another. In fact, each rule is executed only if the parts involved are in specific states (e.g., naïve, active, resting, antigen-presenting).

Besides cell-cell interaction and cooperation, this model simulates the intra-cellular processes of antigen uptake and presentation. Endogenous antigens are fragmented and combined with MHC class I molecules for presentation on the cell surface to CTLs' receptors (this is the cytosolic pathway), whereas exogenous antigens are degraded into small pieces, which are then bound to MHC class II molecules for presentation to T helpers' receptors (this is the endocytic pathway).

The stochastic execution of the algorithms coding for the dynamical rules, results in a sequence of cause/effect events culminating in the production of effector immune cells and setup of immunological memory. The starting point of this series of events is the injection of an antigen which, here, consists of the virus. This may take place any time after the simulation starts (the sequence of events of the SARS-CoV-2 simulation is reported in Appendix A). Initially the system is "naïve" in the sense that there are neither T and B memory cells nor plasma cells and antibodies. Moreover, the system is designed to maintain a steady state of the global population of cells (homeostasis), if no infection take place.

Besides the parameters defining the characteristics of the virus related to attachment, penetration, replication and assembly (i.e., its fitness), the SARS-CoV-2 virus in this model is defined as a set of B-cell epitopes and T-cell peptides consisting of amino acid 9-mers and defining its antigenicity. If the infection is stopped or becomes persistent or even kills the virtual patient it depends on the dose of the virus, its fitness, and the strength of the immune response aroused. All of these variables determine if, and to what degree, the success of the immune system requires the cooperation of both the cellular and the humoral branch, as shown in past simulation studies [33] .

With respect to previous version of the model described in [34] the most important difference is that to improve the peptide-prediction performance, rather than using position-specific-score-matrices (PSSM) to weight the binding contribution of the amino-acids composing the protein segments in the bounds [35] , [36] , we resort to pre-computed ranked lists of T-cell epitopes calculated with the original neural network

NetMHCpan method [37] [38] [39] . This feature, which is described below, follows the choice of a definite HLA set.

The C-IMMSIM model accounts for differences in the HLA haplotype when determining which peptides are presented by antigen presenting cells. To this end, it takes in input a list of such peptides for each HLA molecule considered together with a propensity of each peptide to bind to it. This list is computed by using third party immunoinformatics tools as described in the next section 2.2.

The "HLA haplotype freq search" in the "Allele Frequency Net Database"

(http://www.allelefrequencies.net) was used in order to select two HLA-A, two HLA-B and two DRB alleles which are most prevalent in US population [40] . The result pointed to the following alleles:

HLA-A*02:01, HLA-A*24:02, HLA-B*35:01, HLA-B*40:02, DRB1*07:01 and DRB1*15:01. [44] .

The predicted peptides were classified as strong, intermediate and non-binders based on the concept of percentile rank as given by NetMHCII pan 3.2 server with a threshold value set at 2, 10 and >10% , respectively. In other words, peptides with percentile rank ≤2 were considered as strong binders whereas a percentile rank between 2 and 10% designate moderate binders; peptides with percentile score >10 are considered to be non-binders [44] . The list of CTL and HTL peptides and the relative affinity score is reported in the Appendix C.

It is widely accepted that ageing is accompanied by remodelling of the immune system. With time, there is a decline in overall immune efficacy, which manifests itself as an increased vulnerability to infectious diseases, a diminished responses to antigens (including vaccines), and a susceptibility to inflammatory diseases. The most important age-associated immune alteration is the reduction in the number of peripheral blood naïve cells, accompanied by a relative increase in the frequency of memory cells. These two alterations, are extensively reported in the literature and account for the immune repertoire reduction [45] , [46] . Along with the process called "inflamm-aging", the reduction of immune repertoire is considered the hallmark of immunesenescence [47] .

To model the reduction of immune efficacy we first defined the parameter "immunological competence" by decreasing the lymphocyte counts (hence B, Th and Tc) to reflect a reduction in the repertoire of "naïve" cells with immunological history due to accumulation of memory cells filling the immunological compartment.

In particular, the number of white blood cells is computed as ~

is a normal distribution with average and standard deviation (for each lymphocyte type B, Th and Tc) chosen to reflect the reference leukocyte formula for an average healthy human adult (see Figure 2 ) [48] . 

The infection and the dynamical features of the SARS-CoV-2 viral strain has been characterised by two parameters: i) . corresponding to the infectious viral load at time zero, and, ii) the affinity of the virus spike protein to the ACE2 receptor on target cells, called / . In particular, .~[0 ! ,1 ! ] has been taken randomly in Figure 4 ).

The sequence of events from viral infection leading to a full fledged immune response is detailed in the Appendix A. At each time step of the simulation C-IMMSIM dumps all variables allowing for a detailed analysis of the dynamics. A full output example of a simulation is reported and described in the Appendix D.

We have simulated a large number of infections by varying the parameters identifying both the viral characteristics and the individual immunological competences. The seven age classes considered were 0-9, 10-39, 40-49, 50-59, 60-69, 70-79 and 80+. As already mentioned, the age class determines the immunocompetence parameter which, in turn, sets # and $% as well as the lymphocytes counts in the in-silico individual, we can characterize each simulation by the set of parameters ( ( ), . , / ).

Moreover, due to the stochasticity of the model depending on the random number realisations, each simulation corresponds to a different trajectory in the space of the variables. It follows that each simulation coincides with an in-silico patient with variable immunological characteristics ( ) and, at the same time, infected by a slightly different viral burden ( . and / ).

The intervals within which these parameters vary have been chosen to reproduce the age-class incidence of disease severity of infected individuals. The age-class incidence varies wildly among regions mostly due to a different definition of COVID-19 related deaths. Moreover, due to the lack of confirmation of the causes of death in many cases in periods of high emergency as that of March/April 2020 in Italy, these rates should not be considered strictly but rather indicative of the negative exponential-like relationship of the death incidence [49] , [50] .

To reproduce this age-related incidence of in-silico cases we linked the simulated viral load at a certain time to the clinical status (clinical endpoint). This has been done according to the rationale that a patient whose viral load is still quite high after thirty days from infection can be considered at very high risk of death. In fact in most mild cases, the clinical signs and symptoms (mostly fever and cough) have been reported to resolve within 3 weeks from the diagnosis (which translates in approximately 30 days from infection). Instead after 3 weeks several authors have described severe cases with progressive deteriorating multi-organ dysfunction with severe acute respiratory dyspnea syndrome, refractory shock, anuric acute kidney injury, coagulopathy, thrombocytopenia, and death [51] .

The analogy of some simulation variable to a realistic clinical endpoint allow us to stratify the in-silico patients for a more concrete interpretation of the results. We were able to classify the virtual patients on the basis of the viral load observed at day thirty (indicated by 3. ) and a threshold in one of the three classes:

• Critical: if 3. > , namely, the viral load at day 30 is still high; this class includes weak and late responders;

• Partially recovered: those who are still positive but have a low viral load, meaning that the immune response is controlling the viral replication (i.e., 0 < 3. ≤ ); note that this class includes the asymptomatic;

• Fully recovered (or just Recovered): those who have cleared the virus (i.e., 3. = 0).

According to this definition by choosing the cutoff =120 viral particles per micro-litre of simulated volume, we obtain the stratification of the virtual individuals shown in panel A of Figure 3 . Altogether, i.e., of all in-silico individuals, we get 4.3% of critical cases (broken down in age-classes in panel A), 46.8% of partially recovered (panel B), and 48.8% recovered cases (panel C). These figures sound very much in line with current epidemiological statistics when considering that the recovered cases here simulated include asymptomatics [50] . This results shows an interesting and surprisingly high fraction of in-silico patients in the partially recovered class. This class, in fact, includes patients that, at the end of the simulated period of thirty days, are still positive albeit manifesting an active immune response, regardless being asymptomatic or not. This question is discussed below. These special cases can be better examined in Figure 4 , which shows four distinct exemplifying runs with different outcomes. In the panel A the viremia is shown as a function of time. Red lines correspond to individuals who reach the critical condition 3. > thus falling in the class critical. The green line corresponds to a viral clearance corresponding to a fully recovered case, and the blue line shows a situation in which the virus is not completely cleared but stays below the threshold value . This case corresponds to one of what we call partially recovered as it represents virtual individuals that produce an immune response (cf. same figure, panel B showing the corresponding antibody titers) which turns out to be insufficient to clear the virus. These "unresolved infections" include asymptomatic cases and are worth the further analysis described below.

To note that the two examples of critical outcome (red curves) originate from a quite different initial viral load. Also to note that the fully recovered (green) case starts with a viral load that is higher than one critical case, still the immune response manage to control the infection. The blue curve shows a partially recovered case which greatly decrease the viral load (inset plot of panel A) but does not clear it completely. 

It is worth to clarify that the term "symptom" has no meaning in the in-silico framework until we specify the link between model variables and possible clinical endpoints. Also we should note that we have no concept of comorbodity here that would help in defining the "status" of the virtual patient. To overcome this limitation, (1)

where ( ) is the epithelial count per micro litre of simulated volume and T is the time horizon of 30 days (note that ∈ [0,1]). Indeed, when we plot the distribution of for the cases in the critical and non critical (i.e., partially recovered plus fully recovered) classes separately we obtain what shown in Figure 5 . The plot clearly shows that for critical in-silico patient the damage is much more pronounced than for non critical ones.

This prompt us to use the threshold 0 = 0.63 to set apart patients which have mild infections (about 80% as in reality [52] [53] [54] ) to those having severe disease (15% with dyspnoea, hypoxia, lung changes on images [55] ) or critical illness (5%, respiratory failure, shock, multi organi dysfunction, cytokine storm syndrome [56] ), that is, we label patients with ≥ 0 as symptomatic while those with < 0 asymptomatic.

According to this further stratification patients who are still positive (i.e., 0 ≤ 3. < ) and have no symptoms (i.e., < 0 ) account for about 44% of the simulations which is in line with current estimates of asymptomatic 

We tested the correlation between the antigen abundance (or infective viral load V 0 ) and the severity of the infection. The Mann-Whitney-Wilcoxon (MWW) test shows significant (i.e., p-value< 10 !3 ) difference between infecting viral load V 0 in the three classes critical, partially recovered, recovered. In particular we find that a higher V 0 is a strong correlate of disease severity [57] . Of interest is the fact that there is no significant difference among age groups, that is, V 0 is not predictive of the disease severity with respect to the age [58] (MWW test p-value>0.05).

Significantly, in most critically ill patients, SARS-CoV-2 infection is associated with a severe clinical inflammatory picture based on a severe cytokine storm that is mainly characterised by elevated plasma concentrations of interleukin 6 [59] . In this scenario, it seems that IL-6 owns an important driving role on the cytokine storm, leading to lung damage and reduced survival [60] . The simulation agrees on this finding as the plot in Figure 6 shows. Plotting the peak value of the viral load (i.e., the maximum value attained in the observed period) versus the logarithm of the integral of IL-6 over the whole period (cf. eq(2) in next section 3.5), we see a positive correlation no matter the outcome (recovered, partially recovered, critical). For all age-classes, a critical clinical course is associated to a significantly higher concentration of proinflammatory cytokine IL-6. Panel B of Figure 7 shows the same information for all age-classes lumped together and the difference is statistically significant. The cytokine concentration on the y-axis is calculated as the integral over the whole simulated period (definition in eq (2) 

What observed in the production of IL-6 in younger individuals extends to all cytokines produced during the response to the inflammation. In fact we find that, in general, cytokines' cumulative production during the whole simulated period correlates inversely with the age. Calling 5 the concentration of cytokines x in the simulated volume, where x is one of IL-6, D, IFNg and IL-12, we define 

the cumulative value of cytokines in the whole observation period. Figure 8 shows 678 , $ , 69:; , and 672with respect to age. What Figure 8 shows is that there is a clear reduction of cytokines' production with age.

This, similarly to what discussed in the previous section, is due to the reduced immune activity which indeed is determined by a reduced immunological competence with the age [62] . To justify the apparent contrast of this finding with the fact that elder acute infected individuals are more prone to experience a cytokine storm we should openly regard to one of the limitation of the model, namely, the lack of further cytokine feedbacks that are activated during the course of an extended pneumonia. 

The expression of IFNg by CD4 tended to be lower in severe cases than in moderate cases as shown in panel A of Figure 9 and agrees with [63] . The inverse correlation of interferon-gamma (IFNg) with disease severity is observed in all age groups (panel A and also in panel C when summing all ages-classes). Interestingly, recovered and partially recvovered do not show a meaningful difference when compared to the critical cases (panel C).

IFNg is released by natural killer (NK) cells upon bystander stimulation by danger signals (Rule n.5 in Appendix A) which, in turn, is released by infected/injured epithelial cells upon viral infection (Rule n.3) and

when killed by cytotoxic cells (Rule n.18). This analysis lead us to state that a prompt activation of NK cells in younger individuals due to a higher immunological competence, and a stronger cytoxic response killing infected cells, controls the "acute" production of danger signal impacting on the production of IFNg. 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 7 7.1 7. 

If we use the cumulative value of inflammatory cytokines as variable, namely, 69:< + 678 + + 4:9'

(i.e., the sum of the integrals) and we use the accumulated damage in the epithelial compartments, that is, the fraction of depleted epithelial cells due to the immune cytotoxicity defined in eq(1) (cf. section 3.2) as the discriminating criteria between symptomatic and asymptomatic, we observe what is shown in Figure 10 . Compared with asymptomatic cases, the symptomatic ones more frequently have a markedly higher levels of inflammatory cytokines. The difference of the virtual patients in the two classes is statistically significant (MWW test, p-value< 10 !3 ), which is in line with the clinical finding that show higher inflammatory level in severe disease progressions [63] . This result seems to contrast what stated in section 3.5, namely that younger individuals produce more cytokines but have a less-severe course of the disease. However the explanation provided by the simulation is that those who deal with the infection more rapidly (those including asymptomatics) produce, overall, a smaller amount of cytokines, thus are at lower risk of having a "cytokine storm". On the other hand, an inconclusive immune response chronicisizing the inflammation results in pronounced symptoms (e.g., extended epithelial damage) and ultimately in a cytokine storm.

It has been suggested that in younger individuals several factors contribute to the lower numbers of patients obseved with severe disease, namely: lower number of ACE receptors, overlapping immunity against coronaviruses and a more efficient intact immune system. Panel B is in line with the fact that younger individuals mount a quicker immune response that is generally more efficient than those in elder people thus eradicating the virus in a shorter time.

The key role of the humoral response Figure 12 shows that younger individuals have a higher production of antibodies when compared to elder individuals. This is evidente for both critical and recovered (partial or fully recovered) individuals. However the most striking observation when considering the difference between recovered and critical cases is the gap in antibody titers present in virtually all age classes (panel A). This indicates a strong protective role of the humoral response making a split between recovered and critical patients.

Panel B of Figure 12 shows the corresponding statistics for the cytotoxic T cell (peak value) count per ageclass and critical status. This plot consistently evidences that youngers have a stronger response than elders.

Interestingly, in contrast to the humoral response, in all age classes the cytotoxic response in critical individuals is higher than in recovered ones revealing the attempt of the immune system to counterbalance the unefficacy of the humoral response. Moreover, a further view at the antibody titers reveals that its peak value (i.e., @'5 = max

correlates inversely with the clearance time ( ? ), that is, faster response are obtained with a lower production of antibodies (cf. Figure 13 ). This is in line with the hypothesis that asymptomatic individuals develop a rapid but mild response which clears the infection [64] . 

It should be noted, however, that there are still substantial uncertainties on the data available due to the variable diagnostic accuracy of different serological tests for COVID-19, therefore more well designed large clinical studies are warranted to address this matter ( [65] , [66] ). Interestingly, the same can not be said when cosidering peak values of Tc counts, that is, the cytotoxic response does not correlate, either positively or negatively, with time-to-clearance (not shown).

We have used a logistic regression classification to see if by measuring the antibody titers and the CTL counts at day < 30 we are able to infer the outcome at the end of the simulated period of = 30 days. We call ( = 30) = 3. the viral load at day 30 after the infection. 

The immunological correlates of COVID-19 are far from being clearly elucidated in clinical studies.

Simulation studies can help disentangling the importance of factors such as a reduced ability to mount an efficient (i.e., not off target) immune response due to age or the infective viral load determining the initial viral The model has been tuned for parameters able to reproduce the relationship of age with the disease severity (cf. Figure 3) . Starting from that, any other observation revealed an emergent property of such complex simulation environment. In particular we observe the correlations among infective viral load . and severity, among immunological (in)competence (thus age) and severity, among the overall cytokine levels and symptoms (i.e., a virtual cytokine storm), and, finally, the key role of the humoral response in clearing the infection yet sustained by the cytotoxic activity (cf. Figure 12) . Importantly, we have identified day 25 after infection (which we can roughly associate to about day 15 th -18 th after the appearance of the symptoms) as the time for a predictive measurements of the antibody response to assess the risk of developing a severe form of the diseases. Before that time, our data suggest that the prediction is not statistically meaningful.

The model is restricted in a number of aspects. It simplifies reality and works with a limited number of mechanisms and a reduced diversity. Moreover, it does not reproduce diverse organs and tissues and therefore we cannot observe site-specific pathological problems, including the spatial extension of pneumonia.

Nevertheless the analysis conducted in the present work accounts for such limitations and the results obtained can be reasonably considered independent of such restrictions.

Of course there are some cases reported in the literature in which the course of infection has been extremely long, expecially in severly immunocompromised patients. However, the very complex and lenghty dynamics taking place in those cases are beyond the scope of this study, which instead represent at large the majority of observed cases.

Finally, we should consider that the clinical ground of observation inevitably starts much later than in our model, as people ask for medical attention only after developing symptoms or after knowing of accidentally having been in contact with patients/carriers. Therefore the window of observation we consider in this paper is recapitulating more precisely the infection dynamics of the early days.

Potential study directions should cover the duration of immunity, either natural or induced by the vaccine, including ways to indirectly verify it, the impact of immunesenescence on the elicited immunity or the combined effect of monoclonal antibody and vaccines in potential future terapies.

Despite the extraordinary complexity of the immune system dynamics, the progress of simulation platforms suggests that a more intense interaction between clinicians and researchers in computational model could bring these models to the desidered quality for deployment in the medical field. Appendix D. Example readout of a simulation Panel A of Figure 16 shows the total counts of the B-cells in all phenotypes, that is, memory and not memory, and the three isotypes IgM, IgG1 and IgG2 (i.e., cells that will become plasma B cells producing IgM or IgG antibodies).

Panel B shows the count of antibody-generating plasma cells subdivided in the three classes IgM, IgG1 and IgG2.

Panel C gets into the details of the ABM simulation model by showing the counts of B-cells subdivided according to the internal state assemed. Worth to note that the cells enter the duplication state only after day 10 and until day 20 because besides presenting the viral peptides on their HLA molecules, they need to be stimulated by stimulated cognate helper T cells bearing the "correct" cell receptor (panel D of same Figure   16 ). Note also that upon clearance of the virus (cf. panel A of Figure 15 ) the B-cell population switches back to the "active" state and terminates the presentation of the viral proteins.

Panel D shows cell counts for CD4 T-cell population (total number, memory cells, not memory). Some days after the infection and upon successful interaction with antigen presenting cells, T helper lymphocytes start to duplicate and differentiate into memory. They also foster cytotoxicity (cf. panel A and B of Figure 17) and humoral response (cf. panel B of Figure 16 ) through secretion of cytokines (panel B of Figure 15 ). As for

B cells in panel A, panel E shows Th counts specifying the internal state of the lymphocyte thus revealing the "activation" phase starting quite soon before day 5 and the duplication phase starting immediately after and ending at about day 20. Of note, some cell become anergic around day 15 for lack of "danger" (second) signal upon activation (Rule n.9 in Appendix A). 

Somatic generation of antibody diversity

Somatic Hypermutation of Immunoglobulin Genes

The serial cultivation of human diploid cell strains

Hayflick, his limit, and cellular ageing

T cell anergy

The sound of silence: modulating anergy in T lymphocytes

Clonal anergy: Persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen

Molecular underpinning of B-cell anergy

Tolerance, Danger, and the Extended Family

Danger signals: SOS to the immune system

Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research

Evaluation of MHC class I peptide binding prediction servers : Applications for vaccine research

Definition of supertypes for HLA molecules using clustering of specificity matrices

Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach

Prediction of MHC class II binding affinity using SMMalign, a novel stabilization matrix alignment method

Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools

Reliable prediction of T-cell epitopes using neural networks with novel sequence representations

NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11

Gapped sequence alignment using artificial neural networks: application to the MHC class I system

Improved methods for predicting peptide binding affinity to MHC class II molecules

Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention

Hematology and oncology, Internal medicine

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District

Asymptomatic infection by SARS-CoV-2 in healthcare workers: A study in a large teaching hospital in Wuhan, China

Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Features, Evaluation, and Treatment of Coronavirus (COVID-19)

SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease

SARS-CoV-2: a storm is raging

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Why does COVID-19 disproportionately affect older people?

Clinical and immunological features of severe and moderate coronavirus disease 2019

Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus

Antibody Responses and Their Relationship to Disease Severity

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis

Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents

Measures of the Amount of Ecologic Association Between Species

M internalise, process and present viral peptides on class II HLA; in presence of IFNg they release IL-12

DC phagocytosis & endocytosys: DC phagocyte, internalise, process and present viral peptides on class II HLA (exocytic pathway) but also on class I HLA

Th activation: in presence of danger signal, resting T helper lymphocytes are activated by interaction with peptidebound HLAs on professional antigen presenting cells (M and DC, mainly DC) surface by means of specific interaction with their T-cell receptors (TCR); if no danger is present, the Th cells becomes anergic upon interaction of its TCR with the HLApepide complex 10. Th stimulation by APCs: activated Th interacting with antigen presenting cells (M, DC) • Th duplication: start clone expansion

• Th1 release IFNg • Th2 release IL-4

• release IL-12 in presence of high local concentration of IFNg • Treg release TGFb and IL-10

Th stimulation by B: activated Th interacting with B cells • B duplication: stimulate B cells to start clone expansion; part of the clone become memory • Th duplication: start clone expansion

• Th1 release IFNg • Th2 release IL-4

IL-4, IL-6, IFNb, IL-12, IL-18, IL-2, TGFb and IL23, active T helper cells undergo class switch into Th1 and Th2 13. B differentiation: B cells differentiate to antibody-secreting plasma B cells (PLB)

Isotype switch: B cells perform immunoglobulin class switching, that is, change production of immunoglobulin from the isotype IgM to the isotype IgG 15. Antibodies production: Plasma cells secrete antibodies